NEFL Antibody
- Known as:
- NEFL Antibody
- Catalog number:
- abx008943
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- NEFL Antibody
Related genes to: NEFL Antibody
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: NEFL Antibody
Related articles to: NEFL Antibody
- Recently, complement component 4A (C4A), a complement system protein, and neurofilament light chain (NfL), a neuroaxonal injury biomarker, have been found to be potentially implicated in the pathophysiology of psychosis. This study evaluated C4A and NfL levels before and after risperidone monotherapy in patients with psychosis. - Source: PubMed
Biradar Rakesh RGupta RachnaSrivastava ShrutiJain Seema - To compare chronological age and neurofilament light chain (NfL)-derived age in people with multiple sclerosis (pwMS) and controls, and to explore clinical correlates of the NfL age gap. - Source: PubMed
Publication date: 2026/09/27
Nicolella ValerioPolito CarmelaCriscuolo VincenzoVarelli MarcoFasano StefaniaFiorenza MarianoPascarella GennaroCarotenuto AntonioPetracca MariaLanzillo RobertaCastaldo GiuseppeMorra Vincenzo BresciaSalvatore FrancescoTerracciano DanielaMoccia Marcello - Serum neurofilament-light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient- and disease-level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO). - Source: PubMed
Rival ManonRollot FabienLaurent-Chabalier SabineCasey RomainEl Bahi IlliasseBrocard GuillaumeMarignier RomainTrouillet-Assant SophieVukusic SandraFromont AgnèsLaplaud David AxelMathey GuillaumeMaillart ElisabethMichel LaureRuet AurélieLabauge PierreAyrignac XavierZephir HélèneCiron Jonathande Sèze JérômeKwiatkowski ArnaudPapeix CarolineBranger PierreLebrun-Frenay ChristineBerger EricClavelou PierreHeinzlef OlivierPelletier JeanAl-Khedr AbdullatifCasez OlivierBourre BertrandCréange AlainDavid ThomasMagy LaurentCamdessanche Jean-PhilippeDoghri InèsDos Santos AmélieMura ThibaultAgherbi HananeThouvenot Eric - Given the need to clarify the relationship between biomarkers, cognitive performance, and clinical status in Down syndrome (DS), this longitudinal study examined the influence of baseline clinical diagnosis on the evolution of plasma neurofilament light (NfL) and p-tau217, as well as the predictive value of baseline cognitive performance on biomarker trajectories and clinical conversion within the Alzheimer's disease (AD) continuum. - Source: PubMed
Publication date: 2026/09/24
Fernández AlbertoMolanes-López Elisa MZuluaga PilarVaquero LucíaMoldenhauer FernandoGalván-Román José MBajo RicardoLagunas NataliaGarcía-Alba Javier - Neurofilaments are vital structural components of neurons and play a central role in preserving axonal architecture and function. Among these, neurofilament light chain (NfL) has emerged as a sensitive biomarker of neuroaxonal injury. This chapter delineates the molecular organisation of neurofilaments, tracing their hierarchical assembly from coiled-coil dimers to mature filaments, and emphasises their contribution to axonal stability, calibre regulation, and intracellular transport. It further examines how perturbations in neurofilament homeostasis reflect neuronal damage across a broad spectrum of neurological disorders. Advances in analytical technologies, particularly ultrasensitive immunoassays such as Sioma and ELISA, have enabled robust quantification of NfL in cerebrospinal fluid and blood, facilitating its translation from experimental research into clinical practice. The diagnostic and prognostic relevance of NfL is examined across neurodegenerative, inflammatory, traumatic, and vascular diseases of the nervous system, with particular focus on Alzheimer's and Parkinson's diseases, highlighting its utility for disease monitoring and assessing treatment response. A discussion of clinical factors to consider when assessing NfL for disease diagnosis, along with its current challenges, is provided to draw attention to additional research. Through mechanistic insights spanning protein biology, clinical findings, and biomarker science, this chapter highlights NfL as a robust and non-invasive indicator of neuroaxonal injury applicable across distinct aetiologies. It posits that the systematic incorporation of NfL measurements into clinical workflows may refine nosological classification, enhance diagnostic and prognostic precision, and improve risk stratification at both individual and cohort levels, whilst informing evidence-based therapeutic decision-making and longitudinal patient management across a wide spectrum of neurological conditions. - Source: PubMed
Publication date: 2026/05/26
Rajesh NiranjanaR JasmineJoji RyonaSivakumar SowmyaFrancis Dileep